Fibrobiologics Inc (FBLG)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.81+2.84%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · FBLG
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
FBLG — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-07-24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 22, 2026, FibroBiologics, Inc. (the “Company”) received a Staff Determination letter (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq Staff had determined to delist the Company’s securities from The Nasdaq Capital Market. The Staff Determination stated that the bid price of the Company’s l…
Why it matters: If health care revenue growth speeds up, it could help Fibrobiologics improve its position in a tough market.
Supportive ifHealth care sector revenue growth exceeds 10% year over year.
Worry ifHealth care sector revenue growth remains below 10% year over year.
Why it matters: The earnings report will show if Fibrobiologics can improve its loss-making status. Investors will look for signs of recovery.
Watch forThe earnings report shows a reduction in losses compared to the previous quarter.
Also watch forThe earnings report shows losses that are equal to or worse than the previous quarter.
Why it matters: High losses show money problems. This can hurt investor trust.
Worry ifQ2 losses were worse than -$5 million.
Less concerning ifLosses were better than -$5 million. This shows better cost control.
Why it matters: The company received a notice of delisting. This could affect its ability to raise capital.
Worry ifFibroBiologics fixes the Nasdaq issue and stays listed.
Less concerning ifThe company is no longer on Nasdaq.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$385 on $10,000 · ±3.8% | How much price usually moves either way. |
| Bad day | $1,131 loss on $10,000 · 11.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,488 loss on $10,000 · 94.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A good private placement can provide money for operations and growth.
Supportive ifThe private placement has closed. The company has received the funds.
Worry ifThere are issues or delays in the private placement process.
Why it matters: This offering is important. It helps raise money for operations and development.
Supportive ifThe private placement is complete. It raises $3 million upfront.
Worry ifThe private placement does not close. It raises much less than expected.
Why it matters: High cash burn and losses could harm FibroBiologics' financial health.
Worry ifOperating losses are much lower than in earlier quarters.
Less concerning ifOperating losses stay high or get worse compared to earlier quarters.
Why it matters: Compliance with Nasdaq is crucial for Fibrobiologics to maintain its listing. Failure to comply could lead to delisting.
Worry ifManagement says they fixed compliance issues with Nasdaq.
Less concerning ifManagement says they still do not meet Nasdaq requirements.
Why it matters: New board members with the right skills may change the company's path and choices.
Supportive ifThe company shares plans or partnerships related to the new board members' skills.
Worry ifNo clear changes in strategy or direction after the board members were appointed.